Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 25,800 shares at $110.24 ($2.8M) on 2024-03-27, disclosed to the SEC on 2024-03-29.
Scheduled sale ($2.8M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $105.73 | 1,817 | $192K | 6.8% |
| 2 | $105.73 | 1,817 | $192K | 6.8% |
| 3 | $106.71 | 1,100 | $117K | 4.2% |
| 4 | $107.79 | 1,466 | $158K | 5.6% |
| 5 | $107.79 | 1,466 | $158K | 5.6% |
| 6 | $109.09 | 3,100 |
| $338K |
| 12.0% |
| 7 | $110.24 | 4,544 | $501K | 17.8% |
| 8 | $110.24 | 4,544 | $501K | 17.8% |
| 9 | $110.75 | 2,973 | $329K | 11.7% |
| 10 | $110.75 | 2,973 | $329K | 11.7% |
| Total | $109.16 avg | 25,800 | $2.8M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |